Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...

Mounjaro, manufactured by Lilly, may have emerged as the newest and most effective treatment option after a victory over Novo Nordisk’s Ozempic in clinical trials. For some patients, injectables ...

Eli Lilly plans to release its diabetes and weight-loss drug, Mounjaro, in major global markets like China, India, Brazil, ...

Lilly reported earlier this month that its revenue in the latest fiscal quarter jumped 45% with its new products contributing more than $3.1 billion, driven mainly by strong demand for Mounjaro ...

Eli Lilly's weight-loss drugs include Mounjaro and Zepbound.Sandy Huffaker for The Washington Post/Getty Images Weight-loss drugs such as Ozempic and Zepbound cost $900 to $1,500 for a month's supply.

Lilly figures it won't have to be conservative with launch supplies of orforglipron, unlike the situation with Mounjaro and Zebpound. For its injectable GLP-1s, which were met with immense ...